▲ S&P 500 + | ▲ Stock Advisor + Join The Motley Fool

Accessibility Log In Help

Cheryl Swanson

CherylSwanson

Cheryl has six books published, and currently resides in Hawaii with her husband, her daughter and two dozen surfboards. With a 20-year background as a former medical technology and management consultant, as well as a cancer survivor, Cheryl has a unique perspective on health care. Follow her on Twitter at @uthorcdswanson

Recent Articles by Cheryl Swanson

456752211

Dec 14, 2016 by Cheryl Swanson

Should Johnson & Johnson Jump Into the Rare Disease Market With Actelion? Nope.

J&J has gone big on its bid for Actelion Pharmaceuticals, but here's why it should just go home.

501881776

Dec 13, 2016 by Cheryl Swanson

Could Gilead Sciences' Game-Changing HIV Pill Solve Its Growth Problem?

Gilead's HIV preventing med is not only groundbreaking, it could be the cure to what ails this stock.

484193459

Dec 6, 2016 by Cheryl Swanson

3 Great Dividend Stocks with a Clearance Sale Going on Now

These great stocks offer excellent yields, exceptional growth, and are terrific bargains.

471660478

Nov 28, 2016 by Cheryl Swanson

[TIMESENSITIVE] 3 Biotechs With Save-the-Date Catalysts on Tap

Kite Pharma, bluebird bio, and ACADIA Pharmaceuticals all have price-shaking catalysts approaching that could bring big profits to investors.

200188191-001

Nov 18, 2016 by Cheryl Swanson

Why UnitedHealth Is the Only Healthcare Insurer To Own

With the Affordable Care Act's future in jeopardy, the insurance stock you want to own is the only one with zero exposure to the ACA: UnitedHealth.

200397811-001

Nov 18, 2016 by Cheryl Swanson

You'll Never Guess Who Owns the Most Spectacular New Cancer Drug

Johnson & Johnson’s new cancer treatment isn't just a drug; it’s a $5 billion breakthrough.

Pf501151208

Nov 16, 2016 by Cheryl Swanson

Is Pfizer Rethinking a Company Spin-Off?

A $14 billion spin-off of its over-the-counter drug unit would be great news for investors -- but will it happen?

514411625

Nov 8, 2016 by Cheryl Swanson

3 Stocks Set to Thrive in Pharma's New Price-Conscious World

Worried about the election's impact on pharma? Protect yourself with three great stocks relying on innovation, not price increases, for growth

83214007

Nov 2, 2016 by Cheryl Swanson

2 Takeover Targets In Biotech that Look Ready to Fly

The FDA unexpectedly knocked down Regeneron's new rheumatoid arthritis med, and Johnson &Johnson investors could soon see its competing drug achieve blockbuster status.

536907601

Oct 30, 2016 by Cheryl Swanson

Is Amgen Worth Buying After Its $10 Billion Flop?

With Amgen facing declining demand for its blockbusters, as well as a key failure with its $10 billion pipeline molecule, is this biotech worth buying?

skull and crossbones made of pills drugs poison toxic warning

Oct 26, 2016 by Cheryl Swanson

Unfazed by FDA Warning, Gilead Sciences' Stock Could Be Turning a Corner

Look past the scary headlines, and you may see a comeback in store for Gilead's investors.

95011893

Oct 12, 2016 by Cheryl Swanson

Seven Reasons Celgene is the Best Bet in Biotech

Here’s how Celgene plans to rack up double-digit growth for decades to come.

88831848

Oct 10, 2016 by Cheryl Swanson

Could Tesaro Inc. Be Ready to Fly?

Here's why cancer biotech Tesaro could be readying for lift-off.

182938924

Oct 5, 2016 by Cheryl Swanson

3 Reasons Pfizer's Recent Drop Could Make It a Buying Opportunity

This stock is back in the game with a pipeline full of near-term catalysts, superstar oncology drugs, and a 3.5% dividend yield.

200117665-005

Oct 3, 2016 by Cheryl Swanson

Is Celgene the Smartest Buyer in Biotech?

Celgene’s deal-making genius tilts the odds in favor of its investors.

659527005

Sep 26, 2016 by Cheryl Swanson

How Oncology Could Move the Needle for Johnson & Johnson's Stock

Johnson & Johnson has some oncology drug surprises up its sleeves that could drive further upside for this great stock.

464675081

Sep 22, 2016 by Cheryl Swanson

3 Biotechs With Potential Big-Time Upside

These three high-risk/high-reward biotechs have drugs in late-stage trials and key catalysts just around the corner.

173966582

Sep 21, 2016 by Cheryl Swanson

Juno Therapeutics and Kite Pharma: The Danger of Alarmingly Thin Data

The two biotechs are closing in on explosive potential catalysts, including FDA filings and hoped-for approvals, but thin data could bring nasty surprises for investors.

583823068

Sep 19, 2016 by Cheryl Swanson

Why Johnson & Johnson's New Wearable for Diabetics Should Be a Home Run

Johnson & Johnson is launching a wearable that boldly embraces the huge diabetes market -- and could reignite its lagging medical-devices division.

503893639

Sep 19, 2016 by Cheryl Swanson

Move Over, Intuitive Surgical, Here's How Johnson & Johnson and Google Plan to Build a Better Robot

With J&J and Google planning to build a robotic assistant the size of Star Wars' C-3PO -- and almost as smart as WALL-E -- Intuitive Surgical may need to step up its game.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services